COSA 2020: MDM2 Inhibitors + ER Degraders or CDK4/6 Inhibitors Hold Promise for Advanced, Endocrine-Resistant ER+ Breast Cancer
Cell cycle coregulatory programs are activated synergistically.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.